Pyronaridine

Pyronaridine
A chemical diagram of a Pyronaridine molecule
Clinical data
Other namesPyronaridine tetraphosphate
Routes of
administration		Oral, intramuscular injection, intravenous therapy
ATC code
  • none
Legal status
Legal status
  • CLP (EU): Acute Tox. 3(H301), Eye Dam. 1 (H318), Repr. 2 (H361), Aquatic Chronic 4 (H413)
Identifiers
IUPAC name
  • 4-[(7-Chloro-2-methoxy-pyrido[3,2-b]quinolin-10-yl)amino]-2,6-bis(pyrrolidin-1-ylmethyl)phenol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC29H32ClN5O2
Molar mass518.06 g·mol−1
3D model (JSmol)
SMILES
  • Clc1ccc6c(c1)nc2ccc(OC)nc2c6Nc5cc(CN3CCCC3)c(O)c(CN4CCCC4)c5
InChI
  • InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32) checkY
  • Key:DJUFPMUQJKWIJB-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pyronaridine is an antimalarial drug.[1] It was first made in 1970 and has been in clinical use in China since the 1980s.[2]

It is one of the components of the artemisinin combination therapy pyronaridine/artesunate (Pyramax).[3]

It has also been studied as a potential anticancer drug,[4] and treatment for Ebola. The combination of pyronaridine and artesunate has been evaluated to have a synergistic effect of stronger antiviral effect and less toxicity.[5] The combination of pyronaridine and artesunate is being studied as a possible treatment for moderate to severe SARS-COV-2.[6]

References

  1. ↑ Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. (August 2012). "Review of pyronaridine anti-malarial properties and product characteristics". Malaria Journal. 11: 270. doi:10.1186/1475-2875-11-270. PMC 3483207. PMID 22877082.
  2. ↑ Chang C, Lin-Hua T, Jantanavivat C (1992). "Studies on a new antimalarial compound: pyronaridine". Transactions of the Royal Society of Tropical Medicine and Hygiene. 86 (1): 7–10. doi:10.1016/0035-9203(92)90414-8. PMID 1566313.
  3. ↑ "Pyramax" (PDF). European Medicines Agency. 2016.
  4. ↑ Villanueva PJ, Martinez A, Baca ST, DeJesus RE, Larragoity M, Contreras L, et al. (2018). "Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis". PLOS ONE. 13 (11): e0206467. Bibcode:2018PLoSO..1306467V. doi:10.1371/journal.pone.0206467. PMC 6218039. PMID 30395606.
  5. ↑ Lane TR, Massey C, Comer JE, Anantpadma M, Freundlich JS, Davey RA, et al. (November 2019). "Repurposing the antimalarial pyronaridine tetraphosphate to protect against Ebola virus infection". PLOS Neglected Tropical Diseases. 13 (11): e0007890. doi:10.1371/journal.pntd.0007890. PMC 6894882. PMID 31751347.
  6. ↑ Krishna, Sanjeev; Augustin, Yolanda; Wang, Jigang; Xu, Chengchao; Staines, Henry M.; Platteeuw, Hans; Kamarulzaman, Adeeba; Sall, Amadou; Kremsner, Peter (January 2021). "Repurposing Antimalarials to Tackle the COVID-19 Pandemic". Trends in Parasitology. 37 (1): 8–11. doi:10.1016/j.pt.2020.10.003. ISSN 1471-4922. PMC 7572038. PMID 33153922.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.